Metabolic dysfunction-associated steatotic liver disease (MASLD, the condition formerly known as non-alcoholic fatty liver disease, or NAFLD) has become the most common chronic liver disease in the world, affecting an estimated 25–30% of adults. It is strongly tied to metabolic syndrome, insulin resistance, and excess weight. The encouraging news is that it is largely preventable and often reversible with early nutrition and lifestyle changes.
In 2023, more than 200 international liver experts renamed the condition. "NAFLD" became MASLD and its inflammatory form, "NASH," became MASH. The change did more than swap letters. It removed the stigmatizing word "fatty," dropped the confusing "non-alcoholic," and, most importantly, redefined the disease positively, as liver fat plus at least one cardiometabolic risk factor. This reframes fatty liver for what it truly is: a metabolic condition, which is exactly why nutrition is so central to treating it.
This article reviews the updated terminology and diagnosis, why MASLD is so nutrition-responsive, and the specific, evidence-based dietary and lifestyle strategies that reduce liver fat and protect long-term health.